Andrx abandons brand-name drug business

Share this article:
Andrx is selling off its brand-name pharmaceutical business and ending its supply and distribution contract with Pfizer for its hypertension drug Cardura XL.
Andrx decided to shed its brand-name division to focus on development and distribution. The company will end its contract with Pfizer for Cardura XL because the drug failed to win FDA approval by Dec. 31. Andrx is seeking a refund of the $10 million it paid Pfizer in connection with the agreement for Cardura XL, exercising its right to end the November 2003 deal.
Andrx retained Banc of America Securities to seek offers for its brand-name business, which sustained operating losses of about $31 million for the first nine months of 2004.
Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.